# Rezvilutamide

Source: https://onco.cc/drugs/rezvilutamide/  
OnCo record `rezvilutamide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rezvilutamide is Hengrui's androgen receptor blocker, approved in China in 2022 for high-volume metastatic hormone-sensitive prostate cancer on the CHART trial, where it improved survival over bicalutamide.

## Summary

Jiangsu Hengrui's rezvilutamide (SHR3680) received NMPA approval in June 2022 for high-volume metastatic hormone-sensitive prostate cancer with androgen deprivation, after the CHART phase 3 trial showed longer radiographic progression-free and overall survival than bicalutamide. Further phase 3 trials in non-metastatic and castration-resistant disease are registered. It is not approved outside China.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: SHR3680
- Modality: Oral androgen receptor antagonist
- Mechanism: A second-generation antagonist of the androgen receptor, the class of enzalutamide, apalutamide and darolutamide, blocking androgen signalling in prostate cancer cells.
- Approvals: CN 2022: High-volume metastatic hormone-sensitive prostate cancer with androgen deprivation therapy

## Sources

- ClinicalTrials.gov: trials of Rezvilutamide: https://clinicaltrials.gov/search?intr=SHR3680

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/)
- targets: [Androgen receptor](https://onco.cc/targets/androgen-receptor/)
- trials: [A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer](https://onco.cc/trials/nct07407283/), [A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer](https://onco.cc/trials/nct07241416/), [A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer](https://onco.cc/trials/nct07230106/)

---
JSON: https://onco.cc/api/v1/entities/rezvilutamide.json